Recently, clinical trials have been performed on PPARγ agonists such as rosiglitazone, pioglitazone (thiazolidinedione) and sitagliptin and metformin combination with rosiglitazone for the management of insulin resistance in metabolic syndrome. The gene discussed is PPARG; the disease is metabolic syndrome.